Drawing based on the label description. No photo yet.
“Raloxifene hydrochloride tablets, USP 60 mg tablets are white to off-white, oval, biconvex, film coated tablets, debossed with 'SG' on one side and '306' on other side”
SG 306 pill
Pill with imprint SG 306 is white, oval, 12 mm and has been identified as Raloxifene Hydrochloride 60 mg. It is used for osteoporosis (weak bones). It is supplied by Aphena Pharma Solutions - Tennessee, LLC.
Raloxifene Hydrochloride 60 mg
- Imprint
- SG 306
- Strength
- 60 mg
- Used for
- Osteoporosis (weak bones)
- Color
- White
- Shape
- Oval
- Size
- 12 mm
- Score
- No score line
- Form
- Tablet, film coated
- Manufacturer
- Aphena Pharma Solutions - Tennessee, LLC
- Drug class
- Estrogen modulator
- NDC
- 71610-053, 43598-505, 71610-053-60, 50090-3363, 50090-3363-1, 50090-3363-0, 43598-505-30, 43598-505-01, 43598-505-10, 50228-306, 50228-306-30, 50228-306-20, 71335-1460, 71335-1460-1, 71335-1460-2, 0904-6902, 0904-6902-04
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Raloxifene used for?
Raloxifene is used for osteoporosis (weak bones).
- Medicine type
- Estrogen modulator
Official uses from the US prescribing label
Treatment and Prevention of Osteoporosis in Postmenopausal Women
EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women.
Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis
EVISTA is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.
Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women at High Risk of Invasive Breast Cancer
EVISTA is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.
The effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years. Twenty-seven percent of the participants received drug for 5 years. The long-term effects and the recommended length of treatment are not known.
High risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (LCIS) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer ≥1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. Healthcare professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-800-545-5979. Currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.
After an assessment of the risk of developing breast cancer, the decision regarding therapy with EVISTA should be based upon an individual assessment of the benefits and risks.
EVISTA does not eliminate the risk of breast cancer. Patients should have breast exams and mammograms before starting EVISTA and should continue regular breast exams and mammograms in keeping with good medical practice after beginning treatment with EVISTA.
Important Limitations of Use for Breast Cancer Risk Reduction
- There are no data available regarding the effect of EVISTA on invasive breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of EVISTA.
- EVISTA is not indicated for the treatment of invasive breast cancer or reduction of the risk of recurrence.
- EVISTA is not indicated for the reduction in the risk of noninvasive breast cancer.
From the FDA-approved label on DailyMed (published Sep 02, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows SG and the other side shows 306.
- It is white, oval, 12 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Ingredients
Active: Raloxifene Hydrochloride
Inactive: Citric Acid Monohydrate, Crospovidone, Unspecified, Hypromellose, Unspecified, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol, Unspecified, Polysorbate 80, Povidone, Unspecified, Titanium Dioxide
Also distributed by
A-S Medication Solutions, Dr.reddy’s Laboratories Inc, Sciegen Pharmaceuticals Inc, Bryant Ranch Prepack, Major Pharmaceuticals
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
CP 295
Ultramicrosize Griseofulvin Tablets 125 mg
White, oval, 11 mm
-
C 3
Clobazam 20 mg
White, oval, 11 mm
Used for seizures
Schedule IV
-
G 304
Norethindrone Acetate 5 mg
White, oval, 11 mm
Used for low testosterone and endometriosis
-
PX 4
Pramipexole Dihydrochloride 1.5 mg
White, oval, 11 mm
Used for depression and Parkinson's disease
-
PX 3
Pramipexole Dihydrochloride 1 mg
White, oval, 11 mm
Used for depression and Parkinson's disease
-
G 2611
Terbutaline Sulfate 2.5 mg
White, oval, 11 mm
Used for asthma
Other Raloxifene pills
-
IG 256
Raloxifene 60 mg
White, round, 9 mm
Used for osteoporosis (weak bones)
-
AN057
Raloxifene Hydrochloride 60 mg
White, oval, 12 mm
Used for osteoporosis (weak bones)
- LLILY 4165 Raloxifene Hydrochloride 60 mg White, oval, 12 mm Used for osteoporosis (weak bones)
- IG 256 Raloxifene Hydrochloride 60 mg White, round, 9 mm Used for osteoporosis (weak bones)
- 7290 93 Raloxifene Hydrochloride 60 mg White, capsule, 12 mm Used for osteoporosis (weak bones)
- C79 Raloxifene Hydrochloride 60 mg White, oval, 12 mm Used for osteoporosis (weak bones)
- X 57 Raloxifene Hydrochloride 60 mg White, oval, 12 mm Used for osteoporosis (weak bones)
- 393 Raloxifene Hydrochloride 60 mg White, oval, 12 mm Used for osteoporosis (weak bones)